A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to find the highest dose of ABBV-075 that can be given to subjects with cancer without causing side effects.
Description
This is a Phase 1, first-in-human, dose escalation study of ABBV-075 in participants with advanced cancer to determine the maximum tolerated dose and the recommended Phase 2 dose of ABBV-075.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer,Non-Small Cell Lung Cancer,Acute Myeloid Leukemia,Multiple Myeloma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1412947893 (M14-546)
